[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Cameroon\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":526},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,47,90,115,147,176,206,239,268,302,327,352,379,402,433,454,483,505],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100531694","phase-3-doravirine-versus-dolutegravir-based-antiretroviral-regimens-in-treatment-nave-people-living-with-hiv-1-infection-100531694",false,"NCT06203132","DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection","Phase III, Open-label, Randomized, Multicenter Trial EvaLuating the Non-inferiority of DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection","ELDORADO","Inclusion Criteria:\n\n* Be at least 18 years of age on the day of signing the informed consent.\n* Be HIV-1 positive as determined according to national testing strategies\n* Have a plasma HIV-1 RNA ≥1000 copies\u002FmL within 30 days prior to the randomization,\n* Have HIV treatment indication based on physician assessment according to local treatment guidelines\n* Be naïve to antiretroviral therapy (ART) including investigational antiretroviral agents\n* For women or transgender men of childbearing potential i.e. of childbearing age who are not menopausal, or permanently sterilized (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy) or not refraining from sexual activity: negative urinary test for pregnancy and acceptance to use contraceptive methods\n* Understand the study procedures and voluntarily agree to participate by giving written informed consent for the trial.\n\nNon-inclusion Criteria:\n\n* Has ongoing (pulmonary or extra-pulmonary) tuberculosis\n* Has any other history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate.\n* Is infected with HIV-2 or co-infected with HIV-1 and HIV-2\n* Has received cabotegravir long acting or dapivirine pre-exposure prophylaxis (PrEP).\n* Has received oral pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) in the past three months or has had no negative HIV-1 serology performed\n* Has documented or known resistance or possible resistance to study drugs (in France and where national guidelines recommend screening for primary resistance before starting first-line ART) as defined by the ANRS MIE AC43 Resistance group\n* Has the following laboratory values at screening visit, within 30 days prior to the randomization:\n\n  * AST (SGOT) and ALT (SGPT) \\>4.0 x upper limit of normal\n  * Estimated glomerular filtration rate at time of screening \\\u003C60 mL\u002Fmin\u002F1.73m², based on the CKD-EPI equation\n* Has participated in a study with an investigational compound\u002Fdevice within 30 days prior to signing informed consent or anticipates participating in such a study involving an investigational compound\u002Fdevice during the course of this study.\n* Has used systemic immunosuppressive therapy or immune modulators within 30 days prior to treatment in this study or is anticipated to need them during the course of the study\n* Requires or is anticipated to require any of the prohibited or contraindicated medications noted in the trial protocol.\n* Has significant hypersensitivity or other contraindication to any of the components of the study drugs.\n* Is pregnant, breastfeeding, or expecting to conceive at any time during the study.\n* Has any condition which might, in the investigator's opinion, compromise the safety of treatment and\u002For patient's adherence to study procedure.\n* Is a person under guardianship or deprived of freedom by a judicial or administrative decision","ALL","18 Years",{"count":20,"type":21},610,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Phase III trial evaluating doravirine as an alternative to dolutegravir in treatment naïve people living with HIV-1 infection.",[27],"HIV-1-infection",[29,30,31,32,33],"HIV-1","ART-naïve","doravirine","dolutegravir","non-inferiority","RECRUITING","2026-07-24",{"date":37,"type":38},"2026-07-27","ACTUAL",{"date":40,"type":38},"2025-01-27",{"date":42,"type":21},"2029-01",{"name":44,"class":45},"ANRS, Emerging Infectious Diseases","OTHER_GOV",19,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100644863","preventing-harmful-alcohol-use-among-trauma-patients-in-cameroon-100644863","NCT07677449","Preventing Harmful Alcohol Use Among Trauma Patients in Cameroon","Implementation of a Culturally Adapted Alcohol Screening, Brief Intervention and Referral to Treatment (SBIRT) Program in Cameroon","Inclusion Criteria:\n\n* Adult trauma patients aged 18 years and older presenting to the Emergency Department of Limbe Regional Hospital.\n* Positive alcohol screening based on the Single Alcohol Screening Question (SASQ).\n* AUDIT-C score ≥4 for men or ≥3 for women.\n* Able to provide informed consent.\n* Resident within the study catchment area and available for follow-up.\n* Access to a telephone or another reliable means of contact for follow-up assessments.\n\nExclusion Criteria:\n\n* Severe cognitive impairment preventing participation in study procedures or - provision of informed consent.\n* Severe traumatic brain injury or other medical condition requiring immediate life-saving intervention that precludes participation.\n* Current psychosis or severe psychiatric illness preventing meaningful participation in the intervention.\n* In police custody or other circumstances limiting ability to participate in follow-up.\n* Planned relocation outside the study catchment area during the study follow-up period.\n* Previously enrolled in the study.",{"count":55,"type":21},690,[57],"NA","\\*\\*Brief Summary\\*\\*\n\nAlcohol use is a major contributor to injury burden in Cameroon, particularly among trauma patients presenting to emergency departments. Despite the strong association between alcohol use and injury, structured alcohol screening and intervention programs are not routinely integrated into trauma care in Cameroon. This study aims to evaluate a Cameroon-adapted Screening, Brief Intervention, and Referral to Treatment (SBIRT) program for trauma patients at the Limbe Regional Hospital.\n\nThe study will be conducted in three phases: (1) training emergency department healthcare providers on a culturally adapted SBIRT program; (2) evaluating the feasibility, acceptability, and fidelity of SBIRT implementation in routine emergency care; and (3) assessing the effectiveness of SBIRT in reducing harmful alcohol use among trauma patients. Healthcare workers will be trained to deliver SBIRT, and eligible trauma patients screening positive for risky alcohol use will be enrolled in a randomized waitlist-controlled trial. Participants will undergo alcohol screening using validated tools and will be followed for six months. Outcomes will include alcohol use measured by the Alcohol Use Disorders Identification Test (AUDIT), phosphatidylethanol (PEth) biomarker levels, referral uptake, implementation outcomes, and patient well-being measures.\n\nThe study is expected to generate evidence on the feasibility and effectiveness of integrating alcohol interventions into trauma care in a low-resource setting and inform future scale-up of SBIRT programs in Cameroon and similar settings.",[60,61,62],"Alcohol Use Disorder","Alcohol-Related Injury","Trauma",[64,65,61,66,67,68,69,70,71,72,73,74,75,76,77],"Alcohol Use Disorder (AUD)","Alcohol Screening","Screening, Brief Intervention, and Referral to Treatment (SBIRT)","Brief Intervention","Emergency Department","Trauma Care","AUDIT-C","Referral to Treatment","Substance Use Intervention","Emergency Medicine","Implementation Science","Injury Prevention","Road Traffic Injury","Trauma Patients","NOT_YET_RECRUITING","2026-06-27",{"date":81,"type":38},"2026-06-30",{"date":83,"type":21},"2027-03",{"date":85,"type":21},"2030-08",{"name":87,"class":88},"University of Buea","OTHER",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":98,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":89},"100470223","phase-4-efficacy-of-tenofovir-disoproxil-on-mother-to-child-transmission-of-hbv-in-tokombr-cameroon-in-pregnant-women-100470223","NCT05403047","Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women","Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women Infected With Hepatitis B Virus (HBeAg Positive or With a High Viral Load) and Whose Newborns Had Been Vaccinated at Birth","TOPCHIB","Inclusion criteria:\n\n* Pregnant women with a term of less than 24 weeks of amenorrhea;\n* HBsAg positive ;\n* HBeAg positive or HBeAg negative with a high viral load ( \\> 200 000 UI\u002Fml) ;\n* 16 years old or more on the inclusion day ;\n* Signature of free and informed consent (for pregnant women aged 16 to 21, the participant's consent as well as the authorization of a parent\u002Fadult husband\u002F legal tutor will be collected) which also includes consent for the children\n\nExclusion criteria :\n\n* HIV co-infection;\n* Women treated for HBV;\n* Creatinine clearance \\\u003C30 ml \u002F min;\n* Suspicion of poor monitoring of children's vaccination schedule for HBV (vaccination at birth + boosters);\n* Disease or treatment contraindicating the taking of TDF.","FEMALE","16 Years",{"count":101,"type":21},150,[103],"PHASE4","Pregnant women with HBeAg-positive viral hepatitis b or high viral load will receive Tenofovir disoproxil fumarate (TDF) from the 28th week of amenorrhoea until 6 weeks after delivery. Their newborns will receive the hepatitis B vaccine, starting with one dose at birth and followed by three booster doses, according to the Expanded Programme on Immunisation.\n\nThe investigators hypothesise that a short course of TDF could greatly reduce the risk of HBV MTCT in pregnant women at high risk of MTCT (HBeAg positive or with high viral load).",[106],"Hepatitis B Virus - Chronic Active","2026-06-25",{"date":109,"type":38},"2026-06-29",{"date":111,"type":38},"2023-08-22",{"date":113,"type":21},"2028-02",{"name":44,"class":45},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100640756","pulmonary-rehabilitation-in-african-countries-100640756","NCT07602673","Pulmonary Rehabilitation in African Countries","Respiratory Medicine and Pulmonary Rehabilitation Feasibility Study and Randomised Controlled Trial in Nigeria, South Africa and Cameroon","Inclusion Criteria:\n\n* Male and female adults (\\>= 18 years) with specified clinical diagnosis (typically by detailed clinical history \\[persistent symptoms for ≥6 months\\] plus spirometry and\u002For other available tests, e.g., chest X-ray\\]\n* Individuals with CRDs, specifically COPD, asthma or post-tuberculosis lung disorder\n* Patients with CRDs who have an indication for PR (specifically, these are patients with moderate to severe staged disease who present with reduced exercise\u002Ffunctional capacity, poor quality of life, high disease symptoms, particularly dyspnea) and are medically fit to undergo exercise training (which is to be determined by pre-exercise screening and field tests).\n* Patients with CRDs attending regular follow-up in the respiratory clinics of the selected centres.\n* Patients who are willing and able to provide written or oral (audio recorded) informed consent\n* All levels (primary, secondary, and tertiary) of healthcare professionals, including doctors, nurses, physiotherapists, respiratory therapists, medical assistants, healthcare administrators, pulmonologists, and other formal practitioners working in primary, secondary, and tertiary care settings, who provide services to patients who may potentially require PR.\n* Relevant stakeholders, including policymakers, religious leaders, sports leaders, the pharmaceutical industry, social workers, managers, and hospital\u002Fpractice owners.\n* Willing and able to provide written or oral (audio recorded) informed consent.\n\nExclusion Criteria:\n\n* Patients with other significant chronic co-morbidities such as heart failure, ischemic heart disease, DM, and confusion\u002Fdementia\n* Pregnant women\n* Co-morbidity that is a contraindication to PR (e.g., unstable angina, aortic aneurysm, recent myocardial infarction, acute infection, etc.)\n* Significant cognitive or physical impairment preventing participation in PR\n* Active pulmonary tuberculosis vi. Patient with current or recent disease exacerbations\n* Non-respiratory cause for symptoms (e.g., breathlessness due to heart failure, anaemia)\n* Unable to participate in exercise (e.g., due to severe arthritis or paralysis)\n* Undertaken PR within one year.\n* Unwilling to participate in the study.\n* Unable to give written or oral (audio recorded) informed consent\n* Healthcare professionals who are not involved in the care of patients who require PR, e.g., midwives\n* Having a conflict of interest that may influence the outcome\n* Unable and unwilling to give written or oral (audio recorded) informed consent",{"count":101,"type":21},[57],"Chronic Respiratory Diseases (CRDs) are common disabling conditions worldwide with high prevalence, morbidity and mortality. More than half of the CRD patients live in low- and middle-income countries (LMICs) where resources for identifying the condition, understanding the disease status of individual patients, and overall management are often poor. CRDs in high-income countries (HICs) are dominated by chronic obstructive pulmonary disease (COPD) and asthma, whereas in LMICs, post-tuberculosis (TB) lung disorders, bronchiectasis, and other (often unidentified) respiratory conditions contribute to a significant proportion of CRDs. Pulmonary rehabilitation (PR) is an essential component of evidence-based clinical management guidelines for CRDs, though most of the evidence on PR is disease-specific and generated from HICs. A recent systematic review by the RESPIRE group, with whom we collaborate, revealed that 12 out of 13 studies suggested that PR for patients with CRDs in LMICs was an effective intervention, though the studies were typically at high risk of bias. This highlighted the need for further high-quality large-scale studies in LMICs to assess the enablers and barriers, effectiveness, components, and mode of delivery of PR for CRDs.\n\nIn this feasibility study, the investigators will assess the resource infrastructure, optimal components of the PR programme, relevant CRDs eligibility, and model of service delivery for providing PR in Nigeria, South Africa and Cameroon, and then conduct a pilot randomised controlled trial (RCT). The investigators will also assess potential outcomes, including before and after intervention measurement of functional exercise capacity and relevant patient-reported outcomes. In qualitative interviews, the investigators will explore the barriers and enablers and stakeholders' opinions on implementing PR in each country.\n\nThe investigators will recruit (Nigeria - 30, South Africa - 30 and Cameroon - 30) clinically eligible patients and provide them with 8 weeks of either a centre- or community-based PR incorporating components derived from global PR guidelines and informed by the prior RESPIRE's systematic review and adapted to be deliverable in a low-resource setting. The investigators will assess the patients at baseline, end of the program (8 weeks) and then at 6 months follow-up to assess sustainability. Moreover, along with the quantitative assessment of outcomes (functional exercise capacity, health-related quality of life, dyspnoea severity and other secondary parameters), the investigators will conduct a qualitative interview with a purposive sample of patients, providers, and other health care professionals, e.g., GPs, pulmonologists, physiotherapists. The investigators will synthesise the findings for conference presentations, peer review publications, and advocate for PR with stakeholders.",[126],"Chronic Respiratory Conditions",[128,129,130,131,132,133,134,135,136],"COPD","Asthma","Tuberculosis","Chronic Respiratory Diseases","Africa","Nigeria","South Africa","Cameroon","Pulmonary Rehabilitation","2026-05-18",{"date":139,"type":38},"2026-05-22",{"date":141,"type":21},"2026-09-01",{"date":143,"type":21},"2027-12-01",{"name":145,"class":88},"University of Edinburgh",3,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":89},"100638171","data-driven-lay-first-responder-program-in-cameroon-100638171","NCT07581327","Data-Driven Lay First Responder Program in Cameroon","Implementation of a Data-Driven Pre-Hospital Lay First Responder Program in Cameroon","K-LFR Project","Inclusion Criteria:\n\n\\- Trauma patients presenting to Limbe Regional Hospital and enrolled in the Cameroon Trauma Registry\n\nExclusion Criteria\n\n\\- Trauma patients not included in the Cameroon trauma registry at Limbe regional hospital.",{"count":156,"type":21},1812,[57],"Cameroon experiences a high burden of injury-related morbidity and mortality and currently lacks a formal pre-hospital care system. Lay First Responder (LFR) programs have been implemented in several low-and middle-income countries to improve early injury care by training non-medical community members with high exposure to injury, such as commercial drivers, in basic first aid and safe transport of injured patients.\n\nThe study aims to implement and evaluate a data-driven, context-adapted LFR program in Cameroon using an implementation science approach. Quantitative trauma registry data and qualitative stakeholder interviews will be used to adapt the LFR curriculum to local injury patterns and care gaps. LFR program implementation will be associated with increased chances of survival on presentation and improved trauma outcomes.\n\nThe study is an interrupted time series evaluation of an LFR intervention where prehospital care rates and clinical patterns in the Cameroon Trauma Registry (CTR) patients at Limbe Regional hospital will be compared between historical pre-implementation controls and post-implementation of a data-driven lay first responder training program (the intervention).",[62,160],"Injury",[162,62,163,76,164,165,166],"Lay First Resposnder","Pre-Hospital care","By-stander response","Trauma systems","Emergency Care","2026-05-05",{"date":169,"type":38},"2026-05-12",{"date":171,"type":21},"2026-09",{"date":173,"type":21},"2028-09",{"name":175,"class":88},"Sabrinah Christie",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":184,"sex":98,"minAge":18,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":146},"100565746","improving-menstrual-and-vaginal-health-for-all-100565746","NCT06646185","Improving Menstrual and VAginal Health for All","IMVAHA: Improving Menstrual and VAginal Health for All","IMVAHA","Inclusion Criteria:\n\n* able to provide informed consent;\n* aged 18-35;\n* residing in the recruitment region and expecting to reside in the same region for at least six months following recruitment (Yaoundé\u002F Gounougou, Cameroon; Loreto\u002FLima\u002FMaynas provinces, Peru; or Basel-Landschaft and Basel-Stadt cantons, Switzerland);\n* are native speakers or are able to read and understand one of the following languages in each respective country (German, French, Italian, English or Spanish in Switzerland; French or English in Cameroon; Spanish in Peru);\n* had menstrual cycles of 21-35 days for at least the last 4 months;\n* had menses which lasted at least 3 days for at least the last 4 months.\n\nExclusion criteria:\n\n* experienced a menstrual abnormality with any of the menstrual cycles in the last 4 months (such as oligomenorrhea or amenorrhea, or bleed more than 7 days a month);\n* are pregnant or actively trying to become pregnant;\n* are breastfeeding;\n* used antibiotics and\u002For vaginal antifungals in the last 30 days prior to recruitment;\n* had a vaginal birth in the last 6 months;\n* vaginal surgery, perineal surgery, uterine surgery, miscarriage or abortion in the last 6 months;\n* history of Toxic Shock Syndrome ;\n* positive to detection of the toxic shock syndrome toxin-1 gen (tst) using Polymerase Chain Reaction (PCR);\n* Intrauterine device in situ;\n* under medication (treatment against infectious or chronic disease) at the time of recruitment or during the 3 weeks prior to recruitment;\n* clinical symptoms of vaginal infection;\n* smoker.",true,"35 Years",{"count":187,"type":21},100,[57],"A three-period crossover trial will study the effects of short-term use of 3 menstrual products (menstrual pad, tampon, menstrual cup) on the bacterial composition of the vaginal microbiome in three countries (Peru, Cameroon, and Switzerland). Each crossover period consists of two menstrual cycles, thus resulting in a 6-month trial. Participants will be randomly assigned to one of 6 exposure sequences (different order of products per sequence); in each sequence, participants will adopt each menstrual product for 2 menstrual cycles. Participants will provide vaginal microbiome samples via self-sample swabs at 3 points during each menstrual cycle. Given the crossover design of the study, there is not a dedicated control group.",[191],"Effects of Menstrual Products on the Vaginal Microbiome",[193,194,195,196],"vaginal microbiome","menstruation","crossover study","menstrual products","2026-04-20",{"date":199,"type":38},"2026-04-23",{"date":201,"type":38},"2026-04-15",{"date":203,"type":21},"2026-12-31",{"name":205,"class":88},"Swiss Tropical & Public Health Institute",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":184,"sex":98,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":223,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":238},"100635232","digital-telecytology-for-triage-of-hpv-positive-women-in-cameroon-100635232","NCT07550010","Digital Telecytology for Triage of HPV-Positive Women in Cameroon","Evaluation of Digital Cytology for the Triage of HPV-positive Women in a Same-day \"Test-triage-treat\" Cervical Cancer Screening Strategy in Cameroon","Inclusion Criteria:\n\n* HIV-negative women aged 30-49 and HIV-positive women aged 25-49 years old\n* Ability to understand study procedures and accepting voluntarily to participate by signing an informed consent form (ICF).\n\nExclusion Criteria:\n\n* Pregnancy at the time of screening\n* Previous hysterectomy\n* Known cervical cancer\n* Symptoms of cervical cancer (e.g. metrorrhagia, known pelvic mass)\n* Conditions that can interfere with visualization of the cervix\n* Severe pre-existing medical conditions (e.g. advanced cancer, terminal renal failure)\n* Women who are not able to comply with the study protocol.","25 Years","50 Years",{"count":216,"type":21},1800,[57],"This study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon. Women aged 30-49 years (or 25-49 years if HIV-positive) will undergo primary HPV testing using the GeneXpert system. HPV-positive women will be managed according to an extended HPV genotyping-based algorithm, including immediate treatment, telecytology triage, or follow-up. Histological assessment serves as the reference standard for the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Secondary objectives include evaluation of AI-assisted telecytology and visual inspection with acetic acid (VIA), as well as the acceptability of screening and treatment strategies among women and healthcare providers. The study aims to generate evidence to support scalable, WHO-recommended test-triage-treat approaches in low-resource settings",[220,221,222],"Human Papillomavirus Infection","Cervical Intraepithelial Neoplasia Grade 2 (CIN2)","Cervical Cancer Screening Methods",[224,225,226,227,228],"HPV self-sampling","Telecytology","Artificial intelligence","Extended HPV genotyping","Low-resource settings","2026-04-17",{"date":231,"type":38},"2026-04-24",{"date":233,"type":38},"2025-09-08",{"date":235,"type":21},"2027-09-08",{"name":237,"class":88},"University Hospital, Geneva",2,{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":253,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":265,"locationsCount":267},"100334586","phase-3-low-inr-to-minimize-bleeding-with-mechanical-valves-trial-100334586","NCT03636295","Low INR to Minimize Bleeding With Mechanical Valves Trial","LIMIT","Inclusion criteria:\n\n* Age is 18 or older at the time of enrolment\n* Have had a bileaflet mechanical heart valve implant in the aortic position 3 or more months ago\n* Written informed consent from either the patient or substitute decision maker\n\nExclusion criteria:\n\n* Has a second implanted mechanical valve (any position)\n* Lower boundary of planned INR range is less than 2.0\n* Pregnant or expecting to become pregnant during the study follow-up",{"count":247,"type":21},2625,[24],"This study evaluates the use of a lower INR target (1.5 to 2.5) in patients with a mechanical bileaflet heart valve in the aortic position. This study will inform physicians about whether a lower INR target will decrease the risk of bleeding or increase the risk of blood clot formation and stroke. These results have the potential to reduce the burden of bleeding in patients with a mechanical heart valve who require lifelong warfarin (Coumadin) treatment.",[251,252],"Bleeding Post-mechanical Valve Replacement","Thromboembolism Post-mechanical Valve Replacement",[254,255,256,257,258],"Mechanical valve replacement","Vitamin K antagonist","INR targets","Bleeding","Thromboembolism","2025-12-31",{"date":261,"type":38},"2026-01-06",{"date":263,"type":38},"2019-09-05",{"date":203,"type":21},{"name":266,"class":88},"Population Health Research Institute",35,{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":98,"minAge":213,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":284,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":301},"100606878","optimization-of-cervical-cancer-screening-strategies-among-women-living-with-hiv-effectiveness-and-implementation-of-decentralized-approach-using-a-mobile-team-with-hpv-testing-in-the-western-region-of-cameroon-100606878","NCT07181278","Optimization of Cervical Cancer Screening Strategies Among Women Living With HIV: Effectiveness and Implementation of Decentralized Approach Using a Mobile Team With HPV Testing in the Western Region of Cameroon","Optimization of HPV-based Cervical Cancer Screening Strategies Among Women Living With HIV: Effectiveness and Implementation of Decentralized Approach Using a Mobile Team With HPV Testing in the Western Region of Cameroon","OptiTri_MT","Inclusion Criteria:\n\n* Women\n* HIV infection\n* Age between 25 and 49 years old\n* Receiving or starting ARV treatment\n* Agreeing to participate in the study and having signed the consent\n\nExclusion Criteria:\n\n* Current pregnancy\n* Hysterectomy\n* Treatment of cervical lesions within 12 months\n* Expected follow-up difficulties: planned absence that could interfere with the participation in the study (e.g., travel abroad, relocation, imminent transfer, etc.);\n* Any pathology or concomitant treatment which, in the opinion of the investigators, contraindicates participation or prevents satisfactory participation in the study\n\nDeferred inclusion if\n\n* menstrual bleeding\n* Postpartum (\\\u003C12 weeks after delivery)\n* Clinical signs of cervical or pelvic infection","49 Years",{"count":278,"type":21},1180,[57],"Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. Yet, effective methods for screening and preventing CC are available. The recommanded approach for CC screening is based on multiple steps, including initial test to detect human papillomavirus (HPV) infection, visual inspection to identify women with HPV at risk for precancerous lesion and treatment when required.\n\nDropout may occur at these different steps, compromising the success of the CC elimination strategy. Performing all the screening and treatment sequences in a single visit has been recommanded based on the results of a large South African trial. Yet, in many contexts, including those with limited resources, the screening and treatment activities are performed in multiple visites for logistical reasons, resulting in many dropouts.\n\nDifferent strategies for delivering screening with HPV testing for WLHIV are possible. A first approach (\"centralized approach\") consists of having well equipped reference centres with experienced health workers and referring women to these centers. An alternative consists of having a mobile unit who can bring equipment and health workers and perform the CC screening in the usual places of patient care (\"decentralised\" or mobile team approach). Each of these two approaches has advantages and limitations in terms of coverage, completeness, cost and quality of screening. It is necessary to evaluate them in real life to inform national decision-makers on the best strategy to use in their countries.\n\nThe OptiTri-MU study aims to evaluate and compare the effectiveness of these two strategies for delivering CC screening (\"centralized\" screening versus \"decentralized\" screening). It will also assess the implementation of each strategy and include three sub-studies designed to evaluate :\n\n* the performance of urinary HPV testing.\n* the performance of different methods to identify women requiring a treatment.\n* the risk of post-treatment cervical disease. Design This is a trial in which the intervention (mobile team) will be implemented gradually. All sites starts with the centralized screening strategy. At each period, a new site is ransomly selected and start the the decentralized screening strategy. There will be 6 periods of 10 weeks. The effectiveness of the intervention will be assessed by comparing the outcomes at each site before and after implementation and by comparing the sites with each other. The primary outcome for effectiveness is the screening completeness 120 days after enrollment.\n\nThe study will also assess the implementation of each screening strategy in terms of :\n\n* Success through the measure of fidelity, reach and completeness\n* Identification of adaptation, barriers and facilitating\u002Fleverage factors\n* Perception, feasibility and acceptability of the screening strategies (by patients and health care workers)\n\nOther study objectives include :\n\n* To assess the performance of different methods to identify women requiring a treatment\n* To assess the performance of HPV testing on a urine sample compared with vaginal self-collected or cervical (clinician-collected) samples\n* To assess the efficacy of treatment in terms of post-treatment cervical lesions Study population. Participants will be WLHIV aged 25 to 49 and eligible for CC screening. Health care workers will also be invited to participate to the implementation research. The data collected will be quantitative and qualitative.",[282,283],"Cervical Cancer Screening","HIV",[285,286,283,287,288,289,290,291],"cervical cancer","screening","implementation","resource-limited setting","HPV test","decentralization","thermal ablation","2025-11-24",{"date":294,"type":38},"2025-12-02",{"date":296,"type":38},"2025-04-28",{"date":298,"type":21},"2028-08-01",{"name":300,"class":45},"Institut de Recherche pour le Developpement",6,{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":184,"sex":98,"minAge":213,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":313,"conditions":314,"keywords":316,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":89},"100567541","use-misoprostol-to-optimize-prevention-of-cervical-cancer-100567541","NCT06669533","Use Misoprostol to Optimize Prevention of Cervical Cancer","Misoprostol to Optimizing Prevention of Cancer of the Cervix: A Double-Blind Randomized Controlled Trial","MISOPCx","Inclusion Criteria:\n\n* Diagnosis of Type 3 TZ confirmed on exam prior to randomization\n* Age 25 years or older\n\nExclusion Criteria:\n\n* With Type 1 or 2 TZ prior to randomization\n* Currently pregnant\n* History of hysterectomy\n* Any cancerous lesions\n* Active cervicitis",{"count":311,"type":21},420,[57],"This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.",[315],"Cervical Cancers",[317],"cervical cancers","2025-09-29",{"date":320,"type":38},"2025-10-01",{"date":322,"type":38},"2025-02-25",{"date":324,"type":21},"2027-11-04",{"name":326,"class":88},"University of Alabama at Birmingham",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":17,"minAge":335,"maxAge":18,"enrollmentInfo":336,"targetDuration":338,"studyType":339,"phases":4,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":351},"100347437","hospital-based-registry-of-childhood-cancer-in-pediatric-oncology-units-in-french-speaking-africa-100347437","NCT03803735","Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa","French African Pediatric Oncology Registry","RFAOP","Inclusion Criteria:\n\n1. Any child presenting at any one of the participating units for treatment\n2. Any child with any type of cancer\n3. Any child or adolescent less than 18 years of age.\n\nExclusion Criteria:\n\n1. No cancer found\n2. Age greater than 18 years -","1 Day",{"count":337,"type":21},10000,"12 Months","OBSERVATIONAL","The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group. This data will help to plan and provide correct pediatric oncology treatment and care for this population.\n\nCollecting the data will give much needed information on numbers, stage, treatment and outcome. The register will give data for local and national health authorities in planning pediatric cancer programs.",[342],"Pediatric Cancer",{"date":344,"type":38},"2025-10-03",{"date":346,"type":38},"2016-01-01",{"date":348,"type":21},"2030-12",{"name":350,"class":88},"French Africa Pediatric Oncology Group",14,{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":184,"sex":17,"minAge":359,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":339,"phases":4,"briefSummary":363,"conditions":364,"keywords":366,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":89},"100303102","simian-foamy-virus-transmission-to-humans-100303102","NCT03225794","Simian Foamy Virus Transmission to Humans","Epidemiological and Molecular Aspects of the Interspecies Transmission of Foamy Viruses From Monkeys to Humans: A Model of the Early Stages of Viral Emergence.","Inclusion Criteria:\n\n* Living in a rural zone of Cameroon\n* Being \\> 5 yrs old\n* Having received study information and having provided written consent for self and children, if applicable (for all phases)\n\nExclusion Criteria:\n\n* Having refused to provide consent\n* Being less than 5 years old","5 Years","90 Years",{"count":362,"type":21},1600,"About three quarters of the viral agents that have emerged recently in humans are considered to originate from other animals. These viruses have often evolved and spread into the human population through various mechanisms after the initial contact that resulted in interspecies transmission. However, knowledge of the initial stages of the emergence of viruses and associated diseases is still limited in many cases. Microbiological monitoring in populations at risk of transmission would provide insights into the initiation and early stages of the emergence process.\n\nNonhuman primates (NHPs) share many genetic, physiological, and microbiological features with humans, and are potential sources of many infectious agents. This has been demonstrated for several simian retroviruses. HIV-1 and 2 are believed to have originated from chimpanzee and mangabey viruses, respectively, found in Central and West Africa. The current distribution of the various molecular subtypes of the HTLV-1 oncogenic retrovirus in Africa is mainly the result of numerous instances of interspecies transmission of STLV-1from NHP species in the distant past.\n\nFoamy viruses belong to the Retrovidae family and the Spumavirus genus. They are complex exogenous retroviruses and are very common in many animal species, including primates, cats, cattle, and horses, in which they cause persistent infections.\n\nThe first aim of the work is to study the epidemiological and molecular aspects of the transmission of foamy viruses from monkeys to humans in populations at risk, such as the inhabitants (especially hunters) in the villages of the dense forests of southern Cameroon. It is an area in which NHPs are still very common, with a great diversity of species. The investigators have already shown that the prevalence of foamy viruses is very high in these monkeys and great apes (gorillas and chimpanzees). Contact between these monkeys and the villagers is very frequent, mainly during hunting. The second aim of the project is to study the clinical and biological features of infected people and investigate intrafamilial transmission from infected index cases.",[365],"Simian Foamy Virus Infection (Disorder)",[367,368],"Retrovirus","Viral emergence","2025-09-18",{"date":371,"type":38},"2025-09-22",{"date":373,"type":38},"2010-11-01",{"date":375,"type":21},"2027-12-31",{"name":377,"class":378},"Institut Pasteur","INDUSTRY",{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":98,"minAge":213,"maxAge":276,"enrollmentInfo":387,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":390,"conditions":391,"keywords":392,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":89},"100606562","impact-of-a-single-versus-multiple-visits-on-the-cervical-cancer-screening-completeness-feasibility-and-acceptability-among-women-living-with-hiv-in-cameroon-100606562","NCT07177170","Impact of a Single Versus Multiple Visits on the Cervical Cancer Screening Completeness, Feasibility and Acceptability Among Women Living With HIV in Cameroon","Optimizing Cervical Cancer Screening Strategies With HPV Testing Among Women Living With HIV in Cameroon: Feasibility, Acceptability, and Impact of a Single-visit Test and Treat Approach in a Hospital Center With an HPV Testing Platform","OptiTri_GC","Inclusion Criteria:\n\n* HIV infection\n* receiving antiretroviral therapy\n* living in the department of the study hospital\n\nExclusion Criteria:\n\n* ongoing pregnancy\n* hysterectomy\n* treatment of cervical lesion in the past 12 months\n* Expected follow-up difficulties: planned absence that could interfere with the participation in the study (e.g., travel abroad, relocation, imminent transfer, etc.);\n* Any pathology or concomitant treatment which, in the opinion of the investigators, contraindicates participation or prevents satisfactory participation in the study Inclusion deferred if\n* menstrual bleeding\n* post-partum (\\\u003C12 weeks after delivery)\n* clinicla signs of cervical or pelvic infection",{"count":388,"type":21},1422,[57],"Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. Yet, effective methods for screening and preventing CC are available. The recommanded approach for CC screening is based on multiple steps, including initial test to detect human papillomavirus (HPV) infection, visual inspection to identify women with HPV at risk for precancerous lesion and treatment when required.\n\nDropout may occur at these different steps, compromising the success of the CC elimination strategy. Performing the all screening and treatment sequence in a single visit has been recommanded based on the results of a large South African trial. Yet, in many contexts, including those with limited resources, the screening and treatment activities are performed in multiple visites for logistical reasons, resulting in many dropouts. Strategies based on the differentiated prestation approaches, which propose a simplified management centered on the patients preferences, could guide the adaptation of the single-visit approach to account for contextual constraints while maintaining high effectiveness.\n\nThe OptiTri-GC study aims to design and assess the impact of a differentiated CC screen and treat strategy in a district hospital; It will assess both its implementation and its effectiveness based on the completeness at each stage of the screening cascade. In addition, it will also include three sub-studies designed to evaluate :\n\n* The performance of urinary HPV testing.\n* The performance of different methods to identify women requiring a treatment.\n* The risk of post-treatment cervical disease.\n\nThis study has two periods. During the first period, a single visit approach will be used while differentiated approach will be prepared using participatory research. During the second period, the differentiated approach will be implemented. The screening overall completeness will be compared between the two periods to assess the differentiated approach effectiveness.\n\nThe study will also assess the implementation of each screening strategy in terms of :\n\n* Success through the measure of fidelity, reach and completeness\n* Identification of adaptation, barriers and facilitating\u002Fleverage factors\n* Perception, feasibility and acceptability of the screening strategies (by patients and health care workers) It will assess the participants' stress levels during the screening process and to identify potential psychosocial support strategies and document the experience of WLHIV and health workers during the screening process and the post-treatment follow-up.\n\nOther study objectives include :\n\n* To assess the performance of different methods to identify women requiring a treatment\n* To assess the performance of HPV testing on a urine sample compared with vaginal self-collected or cervical (clinician-collected) samples\n* To assess the efficacy of treatment in terms of post-treatment cervical lesions\n\nMethodology. Participants will be WLHIV aged 25 to 49 and eligible for CC screening. Health care workers will also be invited to participate to the implementation research. The data collected will be quantitative and qualitative.",[282,283],[285,286,283,393,287,288,291,289],"differentiated prestation","2025-09-12",{"date":396,"type":38},"2025-09-16",{"date":398,"type":38},"2024-12-12",{"date":400,"type":21},"2027-05",{"name":300,"class":45},{"id":403,"slug":404,"hasResults":11,"nctId":405,"briefTitle":406,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":184,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":22,"phases":411,"briefSummary":412,"conditions":413,"keywords":418,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":89},"100543052","development-of-a-new-rapid-diagnostic-test-to-support-onchocerciasis-elimination-100543052","NCT06350851","Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination","Obi1","Inclusion Criteria:\n\n* Subjects informed of the objectives of the study and who signed a consent form\n* Subjects without filariasis (for control subjects), or\n* Subjects mono-infected with Onchocerca volvulus, or\n* Subjects mono-infected with Loa loa, or\n* Subjects mono-infected with Mansonella perstans or alternatively co-infected with Mansonella perstans and Loa loa\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Subjects having taken antihelminthic treatment less than 6 months before the inclusion date",{"count":410,"type":21},400,[57],"Onchocerciasis, also known as river blindness, is one of the disease targeted for elimination by the World Health Organization (WHO) in the group of Neglected Tropical Diseases. Existing diagnostic tools for onchocerciasis have limitations that make mapping, epidemiological assessments and verification of elimination of onchocerciasis difficult. It is in this context that WHO, in its 2021-2030 roadmap for onchocerciasis, has identified the development of new diagnostic tests, or the improvement of existing diagnostic tests, as a critical condition for achieving the goal of eliminating onchocerciasis transmission.\n\nTo this end, a series of cross-sectional studies will be carried out in Cameroun over a one year period to collect and characterize biological samples for the development and evaluation of a new rapid diagnostic test for onchocerciasis. The study will target individuals aged 18 and over, mono-infected with one of the filarial species Onchocerca volvulus, Loa loa or Mansonella perstans; and non-infected.\n\nAt the end of this study, data on the endemicity of onchocerciasis, loiasis and mansonellosis in the selected communities will be updated. More importantly, a new rapid diagnostic test will be developed, which can then be used to monitor the activities of onchocerciasis control programs.",[414,415,416,417],"Onchocerciasis","Loiasis","Mansonelliasis","Healthy Volunteers",[419,420,421,422,423],"Onchocerca volvulus","Loa loa","Mansonella perstans","Biplex Rapid Diagnostic Test","Neglected Tropical Diseases","2025-03-05",{"date":426,"type":38},"2025-03-07",{"date":428,"type":38},"2024-04-15",{"date":430,"type":21},"2025-12",{"name":432,"class":88},"Bioaster",{"id":434,"slug":435,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":184,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":146},"100539368","negative-serology-by-immunoenzymatic-test-eia-in-hiv-infected-children-treated-early-with-antiretroviral-in-the-anrs-pediacam-study-pathophysiological-mechanisms-100539368","NCT06302933","Negative Serology by Immunoenzymatic Test (EIA) in HIV-infected Children Treated Early With Antiretroviral in the ANRS-Pediacam Study: Pathophysiological Mechanisms","PediacamNEG","Inclusion Criteria:\n\nCase control study\n\n* Children included and followed in the ANRS 12225 study - Pediacam III\n* Having plasma samples in the bio bank during the above-mentioned periods Case:children with at least one negative HIV serology made by ELISA, permanent or transientduring follow-up.\n\nControl (4 groups)\n\n* HIV-infected children with positive serology and viral load (VL) \\\u003C400 copies \u002Fml\n* HIV-infected children with positive serology and VL ≥400 copies \u002F ml\n* HIV-uninfected children born to HIV-positive mothers\n* HIV-uninfected children born to HIV-uninfected mothers Selection of cases and controls will be matched on gestational age (premature \\\u003C37, term ≥37 weeks) and year of birth (2007-2008 and 2009-2010).\n\nCross sectional study Inclusion criteria\n\n* All children still followed in the ANRS - Pediacam III cohort\n* Written consent of one of the parents or the guardian and assent of the child if aged ≥ 11 years and complete disclosure of HIV statusfor infected children for participation to the study.\n\nExclusion Criteria:\n\n* Refusal by one of the parents or the guardian for the child's participation in the study\n* No assent of the child (if aged ≥ 11 years and with complete disclosure of HIV status, for infected children)",{"count":441,"type":21},451,[57],"The objective of the study is to identify the pathophysiological mechanisms responsible for the induction and maintenance of negative serologies by EIA tests in HIV-infected children treated early with HAART in the ANRS 12225-Pediacam III cohort in Cameroon\n\nThe hypothesis of better control of HIV infection through interactions between immunological, viral, and genetic factors was made to build the following objectives:\n\n* Immunological aspect: lack of humoral response or immune activation\n* Virological aspect: Reduced HIV reservoir size\n* Determine the HLA phenotype in the different groups of children included and the KIR genotypes.",[445],"HIV Infections","2025-01-28",{"date":448,"type":38},"2025-01-30",{"date":450,"type":38},"2024-05-02",{"date":452,"type":21},"2025-08-30",{"name":44,"class":45},{"id":455,"slug":456,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":184,"sex":98,"minAge":461,"maxAge":276,"enrollmentInfo":462,"targetDuration":4,"studyType":22,"phases":464,"briefSummary":465,"conditions":466,"keywords":469,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":89},"100428475","automated-cervical-cancer-screening-using-a-smartphone-based-artificial-intelligence-classifier-100428475","NCT04859530","Automated Cervical Cancer Screening Using a Smartphone-based Artificial Intelligence Classifier","Study Protocol for a Two-site Clinical Trial to Validate a Smartphone-based Artificial Intelligence Classifier Identifying Cervical Precancer and Cancer in HPV-positive Women in Cameroon","Inclusion Criteria:\n\n* Free and informed consent to take part in the study on a voluntary basis\n\nExclusion Criteria:\n\n* No initiation of sexual intercourse\n* Pregnancy at the screening consultation\n* Any condition altering the cervix visualization at the screening consultation (e.g. heavy vaginal bleeding)\n* History of anogenital cancer or known anogenital cancer at the screening consultation\n* Previous hysterectomy\n* Not sufficiently healthy to participate in the study","30 Years",{"count":463,"type":21},5886,[57],"Cervical cancer remains a major public health challenge in low- and middle-income countries (LMICs) due to financial and logistical issues. The World Health Organization (WHO) recommendation for cervical cancer screening in LMICs includes Human Papillomavirus (HPV) testing as primary screening followed by visual inspection with acetic acid (VIA) and treatment. However, VIA is a subjective procedure dependent on the healthcare provider's experience. Therefore, an objective approach based on quantitative diagnostic algorithms is desirable to improve performance of VIA.\n\nWith this objective and in a collaboration between the Gynecology and Obstetrics Department of the Geneva University Hospital (HUG) and the Swiss Institute of Technology (EPFL), our group started the development of an automated smartphone-based image classification device called AVC (for Automatic VIA Classifier). Two-minute videos of the cervix are recorded during VIA and classified using an artificial neural network (ANN) and image processing techniques to differentiate precancer and cancer from non-neoplastic cervical tissue. The result is displayed on the smartphone screen with a delimitation map of the lesions when appropriate. The key feature used for classification is the dynamic of cervical acetowhitening during the 120 second following the application of acetic acid. Precancerous and cancerous cells whiten more rapidly than non-cancerous ones and their whiteness persists stronger overtime.\n\nOur aim is to assess the diagnostic performance of the AVC and to compare it with the performance of current triage tests (VIA and cytology). Histopathological examination will serve as reference standard. Participants' and providers' acceptability will also be considered as part of the study.\n\nThe study will be nested in an ongoing cervical cancer screening program called \"3T-approach\" (for Test, Triage and Treat) which includes HPV self-sampling for women aged 30 to 49 years, followed by VIA triage and treatment if needed. The AVC will be evaluated in this context.\n\nThe study's risk category is A according to swiss ethical guidelines. This decision is based on the fact that the planned measures for sampling biological material or collecting personal data entail only minimal risks and burdens.",[467,468],"Cervical Cancer","HPV",[470,471,472,473,474],"Cervical cancer screening","HPV-related cervical precancer and cancer","Artificial Intelligence","Image processing","Automated VIA Classifier",{"date":476,"type":38},"2025-01-29",{"date":478,"type":38},"2018-08-01",{"date":480,"type":21},"2025-09-30",{"name":482,"class":88},"Prof. Patrick Petignat",{"id":484,"slug":485,"hasResults":11,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":184,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":339,"phases":4,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":89},"100563422","safety-and-effectiveness-of-panaf-premium-tm-snake-venom-antiserum-as-standard-treatment-for-snakebites-100563422","NCT06615960","Safety and Effectiveness of PANAF-Premium TM Snake Venom Antiserum As Standard Treatment for Snakebites","The Safety and Effectiveness of PANAF- Premium TM Snake Venom Antiserum-Pan Africa Administered As a Standard Treatment for Cases of Snakebites- a Phase IV Open Label Trial","PMS","Inclusion Criteria:\n\nPatients of both sex and of any age, with history of snakebites\u002Funknown bites received in study sites\n\n* Willingness to participate in the study by signing the Informed Consent Form (ICF)\n* Presence of one or more signs of envenomation detected by clinical examination including positive clot test. Patient may present with one or more of following visible clinical signs and symptoms of snake envenomation being local or systemic -\n\nDefining local and systemic envenomation\n\n1. Local envenomation- (I) Presence of bite marks with or without oozing of blood, blistering and change in color of skin.\n\n   (ii) Rapidly progressive or massive swelling involving more than half of the bitten limb within few hours of bite (without tourniquet) (iii) Development of enlarged tender lymph nodes draining the bitten part within couple of hours after bite\n2. Systemic envenomation- (i) Neurotoxic syndrome- signs of neuro-paralysis like blurring of vision, double vision, difficulty in swallowing, sleepy feeling, drooping of head, slurring of speech and the voice may become indistinct with shallow breathing, ptosis, ataxia, respiratory paralysis and generalized flaccid paralysis.\n\n(ii) Hemotoxic syndrome- spontaneous systemic bleeding, nausea, vomiting, abdominal pain and abdominal tenderness suggestive of gastro-intestinal or retro-peritoneal bleed and\u002For renal damage, coagulopathy detected by 20 min WBCT with or without external bleeding and shock and a clinical condition\u002Fenvenomation serious enough to administer SA will be eligible for enrolment\n\nExclusion Criteria:\n\n* Participants not able to give consent\n* Participants who are unable to understand the nature, scope, significance and consequences of this clinical trial\n* Pre-existing renal disease, uncontrolled chronic obstructive airway disease, congestive heart failure or previous myocardial infarction and consumption of diuretics, anticoagulants and antiplatelet drugs have been causes for exclusion in a few earlier studies as these illnesses and medications could have altered the clinical and laboratory profile of patients with envenomation.\n* Known history of hypersensitivity to the investigational drug or to drugs with a similar chemical structure\n* Simultaneous participation in any clinical trial involving administration of an investigational medicinal product within 30 days prior to clinical trial beginning\n* Participants with a physical or psychiatric condition which at the investigator's discretion may put the subject at risk, may confound the trial results, or may interfere with the subject's participation in this clinical trial\n* Known or persistent abuse of medication, drugs or alcohol Others conditions may include evidence of clinically significant neurological, cardiac, pulmonary, hepatic or renal disease as far as can be assessed by history of participants, physical examination, and\u002For laboratory examinations.\n\nNB: Patient previously sensitized with equine antiserum such as Tetanus or Diphtheria antitoxin or patients having received treatment with adrenaline, antihistamine, or steroids as a part of treatment at primary health care center and pregnancy will not be excluded. Since this is a post-marketing study, these patients will be included, and this information will be factored in while collating and analyzing data.",{"count":492,"type":21},112,"Snakebite envenomation (SBE) is a major public health problem in many developing countries. Standard snake antivenom (SA) remains the primary treatment and has been shown to reduce mortality in observational studies conducted in several sub-Saharan African (SSA) countries. Although it is relatively available in other endemic contexts such as Asia and Latin America, there have been major challenges with the reliable supply of effective products in sub-Saharan Africa for many years. Premium Serums \\& Vaccines Pvt. Ltd. (PSVPL) recently introduced its SA brand, namely PANAF-Premium TM, manufactured to address unmet treatment needs in the local context. This serum has received WHO approval for use in sub-Saharan Africa and is used in Cameroon with neutralizing efficacy for 24 species represented in Africa.\n\nThis is an open-label, Phase IV post-marketing surveillance study to collect safety and effectiveness data systematically following the administration of PANAF-Premium TM. The study will describe the types, severity, and number of adverse events recorded following the administration of PANAF-Premium TM and its effectiveness for snakebite management. Epidemiological data will also be collected, along with information on the snake species typically responsible for bites in the North region of Cameroon, the type of envenomation, the total dose of SA required for reversal of envenomation, and the total time required for clinical recovery. This will complement the international and national pool of pharmacovigilance data.",[495],"Snake Bites","2024-09-25",{"date":498,"type":38},"2024-09-27",{"date":500,"type":38},"2024-08-26",{"date":502,"type":21},"2025-04",{"name":504,"class":378},"Premium Serums & Vaccines Pvt.Ltd.",{"id":506,"slug":507,"hasResults":11,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":184,"sex":98,"minAge":213,"maxAge":276,"enrollmentInfo":511,"targetDuration":4,"studyType":22,"phases":513,"briefSummary":514,"conditions":515,"keywords":516,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":525,"locationsCount":238},"100468870","hpv-screening-with-triage-by-hpv-genotyping-versus-visual-inspection-with-acetic-acid-100468870","NCT05385406","HPV Screening With Triage by HPV Genotyping Versus Visual Inspection With Acetic Acid","Promoting Comprehensive Cervical Cancer Prevention and Better Women's Health in Low- and Medium Resource Settings HPV Screening With Triage by HPV Genotyping Versus Visual Inspection With Acetic Acid: a Randomized Controlled Trial",{"count":512,"type":21},5500,[57],"Cervical cancer is the leading cause of cancer death among women in sub-Saharan Africa, despite the existence of effective prevention and screening methods. Because vaccination rates against human papillomavirus (causing nearly all cervical cancers) are still insufficient in some low-resource countries, early detection and treatment of cervical lesions at risk of progressing to cancer are crucial components of cervical cancer control. Therefore, it is essential to find the most reliable and appropriate screening strategy in the context of low-resource countries in order to identify women in need of treatment and thus prevent the development of cervical cancer. The objective of our study is to compare two different methods of cervical cancer screening adapted to low-resource settings, in two study centers in Cameroon.",[467],[285,517,286,518],"human papillomavirus","genotyping","2024-05-08",{"date":521,"type":38},"2024-05-09",{"date":523,"type":38},"2022-12-06",{"date":81,"type":21},{"name":482,"class":88},""]